share_log

Further Weakness as COFCO Biotechnology (SZSE:000930) Drops 5.3% This Week, Taking Three-year Losses to 41%

Further Weakness as COFCO Biotechnology (SZSE:000930) Drops 5.3% This Week, Taking Three-year Losses to 41%

中粮科技(SZSE:000930)本周下跌5.3%,使得三年来的跌幅达到41%。
Simply Wall St ·  08/22 19:49

As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term COFCO Biotechnology Co., Ltd. (SZSE:000930) shareholders have had that experience, with the share price dropping 47% in three years, versus a market decline of about 31%. And over the last year the share price fell 32%, so we doubt many shareholders are delighted. Furthermore, it's down 24% in about a quarter. That's not much fun for holders. However, one could argue that the price has been influenced by the general market, which is down 13% in the same timeframe.

作为投资者,值得努力确保您的整体投资组合超过市场平均水平。但是选股的风险在于,你可能会买入表现不佳的公司。我们遗憾地报告,中粮生物技术有限公司(深圳证券交易所股票代码:000930)的长期股东有这样的经历,股价在三年内下跌了47%,而市场跌幅约为31%。在过去的一年中,股价下跌了32%,因此我们怀疑许多股东是否感到高兴。此外,它在大约一个季度内下降了24%。对于持有者来说,这并不好玩。但是,有人可能会争辩说,价格受到了大盘的影响,同期股价下跌了13%。

After losing 5.3% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.

在上周下跌了5.3%之后,值得研究该公司的基本面,看看我们可以从过去的表现中推断出什么。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

沃伦·巴菲特在他的文章《格雷厄姆和多兹维尔的超级投资者》中描述了股价如何并不总是能合理地反映企业的价值。通过比较每股收益(EPS)和股价随时间推移的变化,我们可以了解投资者对公司的态度如何随着时间的推移而变化。

COFCO Biotechnology saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.

中粮生物科技的股价在三年中下跌,其每股收益也下降至亏损。由于该公司已跌至亏损状态,因此很难将每股收益的变化与股价的变化进行比较。但是,我们可以说,在这种情况下,我们预计股价将下跌。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下图中看到 EPS 随时间推移的变化(点击图表查看确切值)。

1724365779611
SZSE:000930 Earnings Per Share Growth August 22nd 2024
SZSE: 000930 每股收益增长 2024 年 8 月 22 日

It might be well worthwhile taking a look at our free report on COFCO Biotechnology's earnings, revenue and cash flow.

可能值得一看我们关于中粮生物科技收益、收入和现金流的免费报告。

What About The Total Shareholder Return (TSR)?

那么股东总回报(TSR)呢?

We'd be remiss not to mention the difference between COFCO Biotechnology's total shareholder return (TSR) and its share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. COFCO Biotechnology's TSR of was a loss of 41% for the 3 years. That wasn't as bad as its share price return, because it has paid dividends.

如果不提中粮生物科技的股东总回报率(TSR)与其股价回报率之间的差异,那就太失职了。股东总回报率是一种回报计算方法,它考虑了现金分红的价值(假设收到的任何股息都经过再投资)以及任何贴现资本筹集和分拆的计算价值。中粮生物科技的股东总回报率在3年内下降了41%。这还不如其股价回报率那么糟糕,因为它已经支付了股息。

A Different Perspective

不同的视角

We regret to report that COFCO Biotechnology shareholders are down 32% for the year. Unfortunately, that's worse than the broader market decline of 16%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 4% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. You could get a better understanding of COFCO Biotechnology's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

我们遗憾地报告,中粮生物科技股东今年下跌了32%。不幸的是,这比整个市场16%的跌幅还要严重。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本发展。遗憾的是,去年的业绩结束了糟糕的表现,股东在五年内每年面临4%的总亏损。我们意识到罗斯柴尔德男爵曾说过,投资者应该 “在街头流血时买入”,但我们警告说,投资者应首先确保他们购买的是高质量的企业。通过查看这张更详细的收益、收入和现金流历史图表,你可以更好地了解中粮生物科技的增长。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).

如果你想和管理层一起购买股票,那么你可能会喜欢这份免费的公司清单。(提示:其中许多未被注意且估值诱人)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发